Last reviewed · How we verify
SUSTOL
At a glance
| Generic name | SUSTOL |
|---|---|
| Also known as | Granisetron extended-release injection for subcutaneous use |
| Sponsor | Heron Therapeutics |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site reactions
- Constipation
- Fatigue
- Headache
- Diarrhea
- Abdominal pain
- Insomnia
- Dyspepsia
- Dizziness
- Asthenia
- Gastroesophageal reflux
Serious adverse events
- Injection site infections
- Syncope
- Pancreatitis
- Atrial fibrillation
- Anaphylaxis
- Serotonin syndrome
- Serious injection site reactions
- Elevation of serum transaminase levels
- Hypersensitivity reactions
- Urticaria
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1,PHASE2)
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (PHASE3)
- A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
- Cisplatin Disposition and Kidney Injury (PHASE3)
- Staccato® Granisetron Single Dose PK (PHASE1)
- Tick-borne Encephalitis and Borrelial Antibodies in Serum (NA)
- Granisetron 1 mg Tablets Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUSTOL CI brief — competitive landscape report
- SUSTOL updates RSS · CI watch RSS
- Heron Therapeutics portfolio CI